TXA127 is a synthetic form of Angiotensin (1-7) currently in development by Constant Therapeutics. It is being trialed as a drug to treat COVID-19.
The CAS# of TXA127 is 51833-78-4.
See also
- List of COVID-19 ARB trials - page collecting information on trials of renin-angiotensin system modulating drugs for COVID-19.
